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Tissue regeneration using human adipose derivedmesenchymal stem cells (hASCs) has significant potential as a novel treatment for
many degenerative bone and joint diseases. Previous studies have established that age negatively affects the proliferation status and
the osteogenic and chondrogenic differentiation potential of mesenchymal stem cells. The aim of this study was to assess the age-
related maintenance of physiological function and differentiation potential of hASCs in vitro. hASCs were isolated from patients of
four different age groups: (1) >20 years (𝑛 = 7), (2) >50 years (𝑛 = 7), (3) >60 years (𝑛 = 7), and (4) >70 years (𝑛 = 7). The hASCs
were characterized according to the number of fibroblasts colony forming unit (CFU-F), proliferation rate, population doubling
time (PDT), and quantified parameters of adipogenic, chondrogenic, and osteogenic differentiation. Compared to younger cells,
aged hASCs had decreased proliferation rates, decreased chondrogenic and osteogenic potential, and increased senescent features.
A shift in favor of adipogenic differentiation with increased age was also observed. As many bone and joint diseases increase in
prevalencewith age, it is important to consider the negative influence of age onhASCs viability, proliferation status, andmultilineage
differentiation potential when considering the potential therapeutic applications of hASCs.
1. Introduction
Mesenchymal stem/stromal cells (MSCs) hold great promise
as a novel therapeutic option for use in tissue regeneration.
Because of their multilineage differentiation capacity, MSCs
are considered as a potential therapeutic tool for treating a
wide range of pathologies, especially bone and cartilage dis-
orders such as osteoarthritis, osteoporosis, and osteonecrosis
[1–3]. Numerous preclinical and clinical studies, using the
ability of MSCs to repair bone and cartilage, have shown
promising results in musculoskeletal regeneration of chon-
dral and osteochondral lesions [4–7]. This lends hope for
MSCs to be potentially used in daily clinical practice.
Beside proliferative and multilineage differentiation
potential, MSCs have an immunomodulatory effect that
is dependent on cell-cell contact or mediated through the
secretion of immunosuppressive molecules [8, 9]. The ability
of MSCs to secrete membrane derived vesicles (MVs), rich
in a wide range of growth factors, antiapoptotic factors, and
anti-inflammatory molecules, is currently considered as a
novel molecular mechanism with significant therapeutic
potential [10, 11]. Multipotent cells have been isolated from
many sources including adipose tissue, bone marrow, and
the umbilical cord [12, 13]. Traditionally, human MSCs are
isolated from an aspirate of bone marrow harvested from the
iliac crest or the acetabulum. However, the most common
and effective way of acquiring the cells is from adipose tissue
[14, 15]. Adipose derived mesenchymal stem cells (ASCs)
are easily obtained from patients during surgery or through
minimally invasive procedures. Results from a number of
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animal studies have confirmed that ASCs can be successfully
used to treat musculoskeletal defects in vivo [16–18].
In humans, the most common disease of the joints is
osteoarthritis (OA) [19]. The prevalence of OA increases
with age and patients with obesity are at increased risk [20].
Moreover, articular cartilage injuries, which originate from
fractures and dislocations, lead to the development of post-
traumatic osteoarthritis (PTOA) [21]. Due to articular pain,
PTOA causes decreased joint function and disability [21].
Clinical and epidemiologic experience indicates that preva-
lence of PTOA after joint surface fracture is strongly depen-
dent on a patient’s age. Adults in their 20s and 30s are signif-
icantly less likely to develop PTOA in injured joints as com-
pared to adults over the age of 50. Although cartilage displays
a very limited capacity for self-repair, it is believed that MSCs
might be the key to complete cartilage regeneration [22, 23].
Studies conducted over the past few years have suggested
that aging impacts various MSC properties [24, 25]. This
effect is most clearly illustrated by changes in two specific
parameters: osteogenic differentiation and proliferation [12,
26–28]. However, there is evidence to suggest that the amount
of MSCs, their proliferation rate, and population-doubling
potential diminish with a patient’s age. Moreover, an age
dependent correlation between the proliferative potential of
MSCs and cell apoptosis has been described [29]. Similar
effects have been reported for periosteal progenitor cells and
hematopoietic stem cells [30, 31]. These findings suggest that
the regenerative potential of MSCs is downregulated with
age and points to a possible limitation in their potential
therapeutic use.
In order to draw a conclusion on the age-related mainte-
nance of physiological function and differentiation potential
of human ASCs in vitro, this study assessed several param-
eters: the number of fibroblasts colony forming unit (CFU-
F), proliferation rate, population doubling time (PDT), and
quantified parameters per lineage for osteogenic, adipogenic,
and chondrogenic differentiation. This allowed us to further
address a possible interdependence between viability and
osteogenesis, adipogenesis, and chondrogenesis of MSCs.
2. Materials and Methods
To study the influence of age on the viability, morphology,
and in vitro differentiation potential of humanASCs (hASCs)
cells, the cells from individuals >20, >50, >60, and >70
years old were investigated. Mesenchymal stem cells were
characterized for proliferation rate and CFU-F, along with
measurements of population doubling time (PD), superoxide
dismutase (SOD) activity, cellular senescence, apoptosis, and
differentiation potential.
2.1. Experimental Groups. In subsequent experiments, cells
were recruited and divided into four groups based on the
donor’s age, both male and female healthy subjects (the
number of males and females was equal): (1) >20 years (mean
age 24 ± 1.4 years; 𝑛 = 8), (2) >50 years (mean age 57.5 ± 0.7
years; 𝑛 = 8), (3) >60 years (mean age 67 ± 1.4 years; 𝑛 = 8),
and (4) >70 years (mean age 75 ± 2.8 years; 𝑛 = 8).
2.2. Cell Collection and Isolation. All cell handling procedures
described herein were performed in accordance with the
ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments and were approved by the
Local Bioethics Committee of Wroclaw Medical University
(registry number KB-177/2014). Written, informed consent
for using tissue samples for research purposes was obtained
from each and every patient prior to surgery.
Human mesenchymal stem/stromal cells were isolated
from subcutaneous adipose tissue. Patients’ fat biopsies
(patient age ranged from 22 to 77 years) were obtained
during total hip/knee arthroplasty or other open procedures
connectedwith fracture reduction and fixation. Samples were
placed in Hanks’ balanced salt solution (HBSS) (Sigma-
Aldrich, Germany) and transferred to the laboratory. Accord-
ing to a standard protocol [32], tissue samples were washed
two times in HBSS with 1% antibiotic solution (Penicillin/
Streptomycin/Amphotericin b, Sigma-Aldrich, Germany)
and separated using surgical scissors. The minced tissue was
digested in collagenase type I solution (1mg/mL, Sigma-
Aldrich, Germany) for 40 minutes at 37∘C. After centrifu-
gation (1200×g, 10min) the supernatant was discarded and
the pellet containing the cells was resuspended in culture
medium and placed in a cell culture flask.
2.3. Cell Culture. Cells were maintained at constant condi-
tions in an incubator (37∘C, 5%CO
2
and 95%O
2
) throughout
the experiment. The primary culture was plated in a T-25
culture flask and cultured on Dulbecco’s Modified Eagle’s
Medium (DMEM, Sigma-Aldrich, Germany) with nutrient
F-12 Ham, 10% of Fetal Bovine Serum (FBS, Sigma-Aldrich,
Germany), and 1% antibiotic solution and then transferred
to a culture flask. The primary hASC culture was designated
“passage 0.” The culture medium was changed every three
days until the cells reached approximately 80% confluence.
Adherent cells were detached from the flask using TrypLETM
Express (Life Technologies, Poland). Cells were passed three
times before starting the experiments. For viability, 7-day test
cells were cultured in DMEM/Ham’s F12 medium, supple-
mented with 10% FBS and with 1% antibiotic solution.
For chondrogenic, osteogenic, and adipogenic differen-
tiation experiments, hASCs were cultured in STEMPRO®
Adipogenic, Osteogenic and Chondrogenic Differentiation
Kits (STEMPRO, Life Technologies, Poland).
The test cells were maintained in 24-well plates and inoc-
ulated at concentration of 30 × 103 cells per well. The media
was changed every two days. Chondrogenic and osteogenic
stimulation was conducted for 21 days, whereas cells were
cultured in adipogenic medium for 14 days.
2.4. hASC Characterization. The purity of MSCs was verified
using fluorescent-activated cell sorting (FACS). The absence
of the hematopoietic marker CD34 and the lymphocyte com-
mon antigen CD45, the presence of mesenchymal markers
(CD90, CD73b, CD44, and CD29), and the cell’s ability to
differentiate into chondroblasts, osteoblasts, and adipoblasts
confirmed that the obtained cells were in fact MSCs.
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2.5. hASCs Clonogenic and Proliferation Potential. The clono-
genic potential of hASCs from each group was tested by
colony forming unit-fibroblastic (CFU-F) assay. The cells
were seeded at density 1 ∗ 103 cells/well and the medium was
changed every 3 days. Cell clusters of more than 50 cells were
considered colonies and were counted after 1 week. Experi-
ments were performed in duplicate, and CFU-Fs were
counted by 2 different operators. The efficiency of the ability
to form colonies was calculated using a formula described
previously [32].
The proliferation factor of hASCs was evaluated using
a resazurin assay kit (TOX8, Sigma-Aldrich), following the
manufacturers protocol. Test was performed on the 2nd, 5th,
and 7th days of the experiment. Based on absorbance, the
proliferation factor and PDT were calculated according to a
previously described method [33].
2.6. hASCs Morphology. Growth pattern and cell morphol-
ogy analysis was performed on the 7th day using an
inverted, fluorescence microscope (AxioObserverA1, Zeiss)
and a scanning electronmicroscope (SEM; EVO LS15, Zeiss).
Evaluation of hASCs morphology included analysis of mito-
chondria, nuclei, and Golgi apparatus localization, as well as
determination of cytoskeleton development. The mitochon-
dria were stained using a rhodamine-based dye, MitoRed
(Sigma-Aldrich, Germany), whereas the nuclei were stained
using diamidino-2-phenylindole (DAPI). The cytoskeleton
was dyed using atto-488-labeled phalloidin. Nuclei and
cytoskeleton staining was performed after cells were fixed
with 4% paraformaldehyde. Procedures involving fluores-
cence staining were performed in accordance with manufac-
turers’ instructions and methods described previously.
After chondrogenic differentiation, cells were stained
with 0.1% aqueous solution of SafraninO (specific for proteo-
glycans). Additionally, after osteogenic and adipogenic differ-
entiation, the presence of calcium deposits and intracellular
lipid vesicles was confirmed with Alizarin Red and Oil Red O
staining, respectively.
Photographs were acquired using a PowerShot Camera
(Cannon).
For SEM imaging, cells were prepared as was described
earlier [34]. Briefly, postfixed cells were washed with distilled
water and dehydrated in a graded series of ethanol dilutions
(from 50% to 100%, every 10%). Dried samples were sputtered
with gold and placed in the microscope chamber. Morphol-
ogy of cells was determined using an SE1 detector at 10 kV of
filament tension (SEM, Zeiss Evo LS 15).
2.7. Quantitative Collagen Types I and II, Aggrecan, Bone
Morphogenetic Protein-2, Leptin, and Adiponectin Assays.
The total concentration of chondrogenesis specific markers,
Collagen type I (Col-I), Collagen type II (Col-II), Aggrecan
(ACAN), and Bone Morphogenetic Protein-2 (BMP-2), was
measured by enzyme-linked immunosorbent assay (ELISA)
in collected supernatants derived from hASCs cultured in
chondrogenic differentiation medium. In order to evaluate
adipogenic differentiation efficiency, the concentration of
adiponectin (ADIQ) and leptin (LEP) in the adipogenic
differentiationmediumwasmeasured after 14 days of culture.
Bone Morphogenetic Protein-2, ACAN, and Col-I ELISA
kits were purchased from R&D Systems (R&D Systems,
Abingdon, UK), and Col-II, ADIQ, and LEP kits were
purchased from EIAab (Wuhan EIAab Science Co., China).
The concentration of proteins was presented as a ratio of
protein weight and supernatant volume (w/v).
2.8. Quantitative Reverse-Transcription Polymerase Chain
Reaction. Expression of cartilage-specific markers (Col-II
and ACAN), osteoblast-specific markers (OPN, Col-I, OCL,
and BMP-2), and adipocyte specific-markers (LEP, ADIQ,
and PPAR-𝛾) were analyzed by quantitative real-time PCR.
Total RNA was isolated from cells by the phenol-chloroform
method [35]. DNA-free RNA was prepared using DNase I
RNase-free kit (Thermo Scientific, USA).
The primer sequences used in the study are shown in
Table 1. CFX ConnectTM Real-Time PCR Detection System
(Bio-Rad, USA) was used for PCR cycling. The PCR mixture
contained 500 ng cDNA, 500 nM PCR primers, and Real-
Time 2x PCR Master Mix SYBR B (A&A Biotechnology,
Poland).The PCR reaction profile consisted of initial enzyme
activation at 95∘C for 2min, followed by 45 cycles of denat-
uration at 95∘C for 30 sec, annealing 30 sec with temper-
ature dependent on the primer sequences (60∘C GAPDH;
61.5∘C Col-I; 67.1∘C BMP-2; 64.8∘C OPN; 67.5∘C OCL; 60∘C
LEP; 60∘C ACAN; 60∘C Col-II; 60∘C ADIQ; 60∘C PPAR-𝛾),
and extended at 72∘C for 30 sec with a single fluorescence
measurement. The series of cycles were followed by a melt
curve analysis to ensure reaction specificity. The expression
level of each gene was normalized to the housekeeping gene,
GAPDH. Subsequently, the relative gene expression (Qn) was
calculated in relation to the GAPDH gene [36].
2.9. Oxidative Stress and Senescence. Prior to assessing the
level of oxidative stress, cells were cultured in normal DMEM
growth medium without phenol red. Superoxide dismutase
(SOD) activity wasmeasuredwith the commercially available
SOD Assay kit (Sigma-Aldrich, Germany), whereas the level
of nitric oxide (NO) was estimated using Griess reagent
kit (Life Technologies, USA). The production of ROS was
determined by measuring H2DCF-DA (Life Technologies,
USA). All procedures were performed in duplicate, according
to the manufacturer’s instructions.
As an indicator of senescence in cells, SA-𝛽-galactosidase
staining was performed, using Senescence Cells Histochem-
ical Staining Kit (Sigma-Aldrich, Germany). After staining,
according to the manufacturer’s protocol, supernatants were
collected and measured for absorbance at 420 nm.The num-
ber of viable cells and dead cells was assessed using Cell stain
Double Staining Kit (Sigma-Aldrich, Germany). The nuclei
of dead cells were stained with propidium iodide, whereas
the nuclei of viable cells were stained with Calcein-AM. Cells
were then observed using epifluorescence microscopy. The
number of dead cells was calculated as percentage of all
viable cells. All procedures were performed in accordance to
manufacturer’s instructions.
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Table 1: Primer sequences used in qPCR.
Gene Primer 5󸀠-3󸀠 Amplicon length (bp) Accession number
ACAN F: GCCTACGAAGCAGGCTATGA 136 NM 013227.3
R: GCACGCCATAGGTCCTGA
ADIQ F: AGGGTGAGAAAGGAGATCC 4155 XM 011513324.1
R: GGCATGTTGGGGATAGTAA
BMP-2 F: ATGGATTCGTGGTGGAAGTG 349 KC294426.1
R: GTGGAGTTCAGATGATCAGC
COL-I F: GTGATGCTGGTCCTGTTGGT 123 NM 000088.3
R: CACCATCGTGAGCCTTCTCT
COL-II F: GACAATCTGGCTCCCAAC 257 NM 001844.4
R: ACAGTCTTGCCCCACTTAC
GAPDH F: GTCAGTGGTGGACCTGACCT 286 NM 0017008.4
R: CACCACCCTGTTGCTGTAGC
LEP F: ATGACACCAAAACCCTCATCAA 22 XM 005250340.3
R: GAAGTCCAAACCGGTGACTTT
OCL F: ATGAGAGCCCTCACACTCCTC 292 NM 199173.4
R: CGTAGAAGCGCCGATAGGC
OPN F: AAACGCCGACCAAGGTACAG 213 U20758.1
R: ATGCCTAGGAGGCAAAAGCAA
PPAR𝛾 F: ATGACACCAAAACCCTCATCAA 125 AB565476.1
R: GAGCGGGTGAAGACTCATGTCTGTC
2.10. Statistical Analysis. Group data is presented as mean ±
standard deviation (SD). Data analysis was performed using
GraphPad Prism 5.0 (San Diego, USA). Statistical signifi-
cance was determined using one-way analysis of variance
(ANOVA) with Tukey’s post hoc multiple comparison test. A
𝑝 value of <0.05 was considered statistically significant.
3. Results
3.1. Donor Age Related Changes in hASCs Morphology and
Proliferative Potential. Human ASCs isolated from all four
age groups fulfilled the MSC criteria: (i) typical plastic
adherent growth; (ii) expression of CD44, CD73, CD90, and
CD105 and absence of surface antigens CD34 and CD45
(Figures 1(a) and 1(b)); (iii) in vitro differentiation potential
toward osteogenic, adipogenic, and chondrogenic lineages
(Figure 1(c)). We did not observe any differences in regard to
the percentage of MSC surface antigen expression, although
therewas some variation connectedwith donor age andCD73
expression (Figure 1(b)).
Plastic adherent colonies were observed in all donor sam-
ples. All cells displayed proper fibroblasts-like morphology,
with predisposition to growth in close contact. Fluorescent
staining after 7 days of culture indicated that all cells had the
ability to grow in multilayer form, with centrally positioned
nuclei. However, cells from donors >70 years were flatter
than cells from other groups, with visible giant cells and
signs of apoptosis (Figures 2(a)–2(d)). Additionally, themito-
chondrial activity of MSCs from young and elderly patients
was evaluated by MitoRed staining (Figures 2(e)–2(h)). We
observed that mitochondria in young patients were evenly
distributed within the cells, whereas with increased age they
tended to be located mainly around the nuclei. Scanning
electron microscopy analysis showed that hASCs obtained
from donors in the >20 years age group were characterized
by formation of a greater number of thin cellular projections
(filopodia and lamellopodia) and several MVs located at the
cell boundary (Figures 2(i)–2(l)).
Observations of cell growth kinetics revealed that the
proliferation rate of cells obtained from young donors (>20
years of age) was significantly higher than in older patients,
and the rate increased gradually until cells finally reached
full confluence (day 5) (Figure 3(a)). Growth curves did not
differ significantly between the older donor samples (>50,
>60, and >70). Furthermore, there was a clear association
betweenPDTanddonor age (Figure 3(b)); cells fromyounger
donors reached PDT faster than older patients. Between
the older donor groups, we did not observe significant
differences. Beyond the observation of a correlation between
age and population doubling time, our results showed that the
clonogenic potential of young and oldMSCs sampleswas age-
dependent. The percentage of CFU formation ranged from
0.9% (>70) to 5.7% (>20) (Figure 3(c)).
To validate that the decrease in cell growth results
from age-dependent apoptosis, we calculated the number
of dead cells (Figure 4(c)) marked with propidium iodide
(Figure 4(a) (I)–(L)) and compared it to the number of live
cells (Figure 4(a) (E)–(H)). We confirmed that with increas-
ing donor age, the percentage of dead cells increases, although
not to a level of statistical significance.We also confirmed the
existence of a correlation between p53 and p21 mRNA levels
in MSCs and the donor age (Figures 4(d) and 4(e)).
Moreover, after 7 days of culture, we observed that cells
underwent replicative senescence. This was manifested by
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Figure 1: Characterization of MSCs. (a) Flow cytometry analysis of MSC positive (CD44, CD73b, CD90, and CD105) and negative (CD34
and CD45) surfacemarkers. (b) Flow cytometry analysis determined the percentage of specificmarkers in total analyzed hASCs from patients
differing in age. Quantification of markers revealed no significant differences between groups. (c) Alizarin Red staining of calcium deposits,
Safranin O staining for proteoglycans, and accumulation of lipid droplets dyed with Oil Red O following differentiation into osteoblast,
chondroblasts, and adipocyte lineages.
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Figure 2: Comparison of hASCs morphology from different age groups, evaluated after seven days of propagation. Scale bars: (a–d) 250𝜇m;
(e–h) 300 𝜇m; (i–l) 10 𝜇m.
the expression of senescence associated beta-galactosidase,
which was measured by dye absorption (Figure 4(b)). While
the senescence of cells was more visible in older age
groups through microscopic observations, absorption mea-
surements indicated that even though younger cells showed
lower dye absorption, the differences between groups were
statistically insignificant.
Furthermore, we compared the oxidative stress senes-
cence of cells and apoptosis. The obtained results revealed
that the ROS level (Figure 5(a)) was significantly lower in
young patients (>20) compared to older age groups. Interest-
ingly, we did not detect significant differences in ROS lev-
els between older age groups. The same relationship, also
insignificant, was observed when comparing NO levels
(Figure 5(b)). The lowest NO level was found in the >20
age group and the level increased with donor age. On the
contrary, we observed only slight differences between the
groups in SOD levels (Figure 5(c)).
3.2. The Ability of hASCs to Differentiate into Chondroblasts
Decreases with Age. The ability of hASCs to differentiate into
the chondrogenic cell lineage (samples from all four age
groups) was evaluated based on lineage specific metabolite
production, which was measured by protein and mRNA
levels, as well as through observation using an inverted,
fluorescence microscope and SEM.
At the beginning of the experiment, cells cultured in
the chondrogenic differentiation medium displayed spindle-
shape morphology, without any obvious age-dependent
changes in cell shape or size. After 16 days of culture, chondro-
e-like ASCs spontaneously formed large aggregates. Char-
acteristic chondro-nodules were observed in all investigated
cultures. Cells from the donors >20 years of age formed
smaller aggregates, between which a cellular monolayer was
created with the presence of fibroblast-like cells (Figure 6(a)
(E)).
Histological staining of chondrogenic samples with
Safranin O, after 16 days of induction, showed that the
samples from all investigated donor groups formed nodules.
The analysis of chondro-nodules in SEM showed that cells
from older donors maintained a more spherical shape and
had rare lamellopodia, whereas cells from the >20 years old
group, formed loosely structured aggregates combined with
several small chondro-nodules (Figure 6(a) (E)–(H)).
Results of qRT-PCR revealed significant age-related dif-
ferences in the expression of genes encoding cartilage matrix:
Col-II and ACAN (Figures 6(b) and 6(c)). We found sig-
nificant differences between the >20 years old group and
older patients, whereaswe did not observe significant changes
in ACAN expression between elderly patients. Expression
levels of all matrix proteins were highest in young patients
and decreased with donor age. Quantitative evaluation of
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Figure 3: Comparison of cell proliferation in different age groups. (a) Cell proliferation assay, (b) population doubling time, and (c) fibroblast
colony-forming unit efficiency over seven days. Results expressed as mean ± SD. ∗𝑝 value <0.05.
Col-II and ACAN on an mRNA level was additionally
confirmed on the protein level by an ELISA test (Figures
6(b) and 6(c)). In contrast to gene expression analysis, we
did not observe significant changes between groups in ACAN
secretion. However, analysis of the concentration of Col-II
on the protein level indicated a significant decrease of Col-
II concentration with increasing donor age.
4. Osteogenic Differentiation Potential of
hASCs Decreases with Donor Age
Osteogenic differentiation of young and old hASCs was
evaluated based on extracellular matrix calcification. Mineral
calcium deposits and hydroxyapatite-like structures were
visualized by Alizarin Red staining and observed in all inves-
tigated groups. Noticeably greater nodules were observed in
ASCs from younger donors.This coincidedwith the results of
calcium and phosphorus content in bone nodules, measured
by SEM-EDX (Figure 7(a)). Alkaline phosphatase activity in
cells measured after 7 days and after 14 days was highly
variable between groups, but did not display any significant
changes (Figure 7(b)). No significant correlation between
age and hASC differentiation capacity was observed. Gene
expression analysis ofOPN,OCL, andBMP-2 revealed higher
expression of all investigated osteogenic markers in younger
patients, with only slight differences between older groups
(Figure 8(a)). An exception was the expression of Col-I,
where we observed a similar trend for all donor groups. Simi-
larly, on the protein level, we observed a higher concentration
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Figure 4: Characterization of age-dependent apoptosis. (a) Cells stained for senescence showing cells with 𝛽-galactosidase accumulation
(A–D), Calcein-AM (E–H), and propidium iodide (I–L) for live-dead cells identification. (b) 𝛽-galactosidase absorbance measurement. (c)
Percentage of apoptotic cells calculated from Calcein-AM/propidium iodide staining, (d) evaluation of p53, and (e) p21 on the mRNA level.
Results expressed as mean ± SD. ∗𝑝 value <0.05.
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Figure 5: Levels of oxidative stress in hASCs. (a) Reactive oxygen species, (b) nitric oxide, and (c) superoxide dismutase levels. Results
expressed as mean ± SD. ∗𝑝 value <0.05.
of secreted OPN, OCN, and BMP-2 in young patients and a
higher concentration of Col-I in the elderly (Figure 8(b)).
4.1. Age-Related Changes in hASC Differentiation into
Adipocytes. Qualitative assessment of Oil Red O staining
revealed that, after 14 days, adipogenic induced hASCs
populations produced similar amounts of lipid droplets in all
investigated groups (Figure 9(a)). We did not find differences
between the groups in the number and size of lipid vacuoles
dyed by Oil Red O (Figure 9(a) (A)–(D)). However, slight
differences between groups were visible under SEM, through
which the youngest donor group appeared to have a smaller
amount of lipid droplets. Moreover, the differentiation
response was reduced in the >20 years old group, which was
manifested by lower adiponectin and leptin levels, measured
by both ELISA (Figure 9(b)) and qRT-PCR (Figure 9(c)).
Furthermore, we observed an age-dependent increase in the
mRNA level of PPAR-𝛾 gamma expression (Figure 9(d)).
5. Discussion
The deterioration of the regenerative potential upon aging
has been suspected to be due to functional changes in adult
stem cells. To confirm this hypothesis, we investigated several
distinct parameters including growth curve, proliferation
factor, PDT, and differentiation capacity into chondrogenic,
osteogenic, and adipogenic lineage in hASCs derived from
different donor age groups.
In this study, differences among hASC populations
derived from >20, >50, >60, and >70 years old donor groups
were manifested by cell expansion properties. Our results
found that age significantly affected the growth kinetic and
the PDT of the investigated groups, with evident differences
between young and elderly patients. Interestingly, there were
no significant changes in regard to proliferation activity
between the older patient groups. This observation could
suggest that while proliferative activity of cells decreases
with age, hASCs do not completely lose their proliferative
potential, even in the elderly. However, in clinical practice,
due to the lower proliferative rates of cells isolated from older
patients, it may be necessary to culture and expand MSCs
in vitro for a longer period before clinical use, which may
lengthen the time needed for clinical autologous application
in these patients.
Our data is consistent with results of other studies that
were conducted on bone marrow derived MSCs, which
showed that aging slowed the PDT [37, 38]. In correlation
with growth curve and PDT changes, we observed an age-
dependent reduction in the ability to form single cell-derived
colonies. The number of colony-forming MSCs strongly
correlates with both their culture expansion ability and their
differentiation potential. Taking into account the prolifera-
tion rate, the PDT, and the CFU of cells is important for their
clinical application due to the large number of cells necessary
for therapy.
A reduction in proliferation rate and viability of cells
might be ultimately reflected in cell senescence and apoptosis
[39]. MSCs can undergo only a limited number of cell
divisions in a process called cellular senescence. Senescence
is considered to be a stress response triggered by the acti-
vation of p53 and is highly influenced by oxidative stress
[40]. In our study, we observed age-dependent senescence
manifested by an altered state of growth, which correlates
with decreasing mitochondrial activity, high levels of p53
and p21, and increased activity of 𝛽-galactosidase. Age-
dependent intensification of senescence has been shown in
animal models and confirms that with increasing donor age,
the number of senescent cells accumulating𝛽-galactosidase is
also increasing [41, 42]. Moreover, based on gene expression
analysis, there is experimental evidence suggesting that aging
involves the p53 and p21 pathway. The p21 protein is a
substrate for caspase-3 activity which appears to be activated
by ROS, thereby facilitating apoptotic response [43, 44].
In our experiment, cells derived from older groups had
elevated concentrations of ROS and NO and simultaneously
decreased levels of SOD, which plays an important role as an
antioxidative factor in the cell [45].
Multilineage differentiation potential has been consid-
ered an important quality of MSCs [46]. Although it has
been shown that adult human MSCs can differentiate into
the chondrogenic lineage, little is known about whether this
differentiation capacity is age-dependent. While our results
show that age reduces chondrogenic differentiation poten-
tial of hASCs, this reduction does not necessarily indicate
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Figure 6: Characterization of age related changes in hASCs chondrogenic differentiation potential. (a) Morphology of cells cultured in
chondrogenic medium visualized by Safranin O staining (A–D) and SEM (E–H). Quantitative ELISA analysis and gene expression of (b)
Col-II and (c) ACAN. Results expressed as mean ± SD. ∗𝑝 value <0.05.
that the cells have lost their regenerative potential. In all
investigated groups we clearly observed the proteoglycan-
rich extracellular matrix and the typical round chondro-
like cell morphology, but there were significant differences
in concentration of chondrogenesis markers on protein and
mRNA levels. We observed mRNA upregulation in regards
to cartilage-specific genes Col-II and ACAN. However, there
were significant differences between age groups, favoring
the youngest donor group. This is similar to findings of
Choudhery et al. [24], who also observed that the capacity of
hASCs chondrogenic potential declines with age. Age-related
changes of MSCs chondrogenic potential were investigated
previously in both human and animal studies; however, these
studies were performed mostly on bone marrow stromal
cell (BSMC) models and have reported conflicting results.
Murphy et al. [47] reported an age-related decrease in
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chondrogenic differentiation of human BSMCs. In rodent
and rabbit models, chondrogenesis of BMSCs confirmed
an age-related decrease in the capacity to differentiate [38, 41].
However, De Bari et al. [48] did not observe any correlation
between age and chondrogenic differentiation of multipotent
cells isolated from adult human synovial membranes.
In this study, age-related osteogenic differentiation capac-
ity was consistent with chondrogenic differentiation poten-
tial. We observed an age-related downregulation of cells
osteogenic potential. We also detected that cells derived from
young donors had an increased expression of osteogenic
markers (BMP-2, OPN, and OCL) and were able to form
osteonodules with a higher content of calcium deposits. Our
findings related to MSCs osteogenic potential are supported
by other studies. Choudhery et al. [24] showed a significant
decrease in osteogenic potential of hASCs, which was also
manifested by a decrease in osteocalcin and ALP gene
expression in elderly donors. These observations are in line
with the work of Zhu et al. [17], who reported a decrease
in the osteogenic potential with increasing age. However, no
aging effects were observed when comparing early and late
osteogenesis markers, as well as calcified matrix deposition
for young and old BMSCs [17]. These discrepancies could be
due to the fact that different cells were used in the previously
mentioned experiments, or the different age ranges and
different health statuses of the cell donors.
Due to the fact that degenerative bone and joint diseases
increase in prevalence with age, the age-related decrease in
both chondrogenic and osteogenic differentiation potential
may be a limitation for the therapeutic applications of
hASCs. Future studies should assess ways to overcome the
limitations in age-related differentiation capacity. Further-
more, Matsumoto et al. [49] reported sex based differences
in chondrogenic differentiation and cartilage regeneration
potential in MSCs derived from muscle tissue. Muscle-
derived stem cells (MDSCs) from men displayed greater
chondrogenic differentiation and better cartilage repair as
compared to MDSCs from females [49]. Combined with
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Figure 8: Gene expression and ELISA anaylsis of osteogenic markers. (a) Gene expression analysis and (b) quantitative ELISA analysis of
OPN, Col-I, and OCL. Results expressed as mean ± SD. ∗𝑝 value <0.05.
the effects of aging, sex based differences present a further
potential limitation to clinical application of MSCs. As such,
future studies should also assess sex based differences in
chondrogenic differentiation capacities of hASCs.
In regard to age related adipogenic differentiation, there
were conflicting observations. On the one hand, we did not
observe differences between age groups in the quantity of
lipid droplets accumulation, but on the other hand we have
found that leptin, adiponectin, and PPAR-𝛾 concentrations
were elevated in older patients as compared to the >20 years
old group. It is well known that MSCs may lose their adi-
pogenic activity with donor aging and that thismay be associ-
ated with the development of disease and abnormal stem cell
activity. In vitro research conducted on BMSCs demonstrated
loss of MSC osteogenic and adipogenic potential with aging
[50, 51]. We can clearly state that MSC aging shifts the
differentiation balance in favor of adipogenic differentiation
and decrease osteogenic and chondrogenic differentiation
potential. This was confirmed by the observations of PPAR-
𝛾 expression in our experiment. Activation of PPAR-𝛾 is
associated with increased adipocyte differentiation that sub-
sequently promotes weight gain and obesity. PPAR-gamma
suppresses the differentiation of osteoblasts progenitors,
while shifting cells in favor of adipogenic differentiation [52].
This subsequently may result in decreased osteoclastogenesis
and bone remodeling [52]. In general, the available literature
suggests an overall decrease in differentiation potential of
MSCs with donor age, regardless of species.
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Figure 9: Characterization of age related changes in hASCs adipogenic differentiation potential. (a) Morphology of cells cultured in
adipogenic medium visualized by Oil Red O staining (A–D) and SEM (E–H). Quantitative ELISA analysis and gene expression of LEP (b)
and ADIQ (c). Gene expresion analysis of PPAR-𝛾 (d). Results expressed as mean ± SD. ∗𝑝 value <0.05.
Understanding the influence of age on MSCs proper-
ties is important due to their potential therapeutic use in
musculoskeletal disorders that are widespread among the
elderly. Our results demonstrate that not only the prolifera-
tion status ofMSCs, but also theirmultilineage differentiation
capacity, may provide an argument to restrict MSC-based
therapies to certain individuals. Future studies comparing the
effects of aging on different MSCs populations could help to
optimize treatments by identifying anMSC source that is less
adversely affected by age.
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